RRCancer - Banque cancer ovaire Sherbrooke, Canada

Certification Status: Approved

Registration Status: Completed

Objective: The banque d'échantillons biologiques et de données on ovarian cancer is part of the Banque de tissus et de données of the Réseau de la Recherche en Cancer du Fonds de la Recherche en Santé du Québec and includes partnership with CTRNet. The Banque d'échantillons biologiques et de données provides researchers with normal, benign or neoplastic tissus for studies aiming at identifying new biomarkers for diagnosis of ovarian cancer, for prognostic and for disease classification. The bank also provides ascites for understanding the interactions between this microenvironment and the tumor cells. Samples may be provided to local, provincial and canadian researcher groups if the study is approved by the scientific committee of Banque de tissus et de données of the Réseau de Recherche en Cancer du Fonds de la Recherche en Santé du Québec.

Registered Biobank Name	RRCancer - Banque cancer ovaire Sherbrooke
Biobank Leader	Isabelle Matte
Country	Canada
Email for biobank inquiries	Isabelle.matte@usherbrooke.ca
Principal Investigator	Marilyne Labrie
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).